Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 1999

Primary Completion Date

June 30, 2000

Study Completion Date

August 31, 2003

Conditions
Extrahepatic Bile Duct CancerGallbladder CancerLiver Cancer
Interventions
DRUG

dolastatin 10

Trial Locations (11)

46617

Michiana Hematology/Oncology P.C., South Bend

60068

Lutheran General Cancer Care Center, Park Ridge

60201

Evanston Northwestern Health Care, Evanston

60612

University of Illinois at Chicago, Chicago

60637

University of Chicago Cancer Research Center, Chicago

60640

Louis A. Weiss Memorial Hospital, Chicago

61602

Illinois Oncology Research Association, Peoria

62526

Cancer Care Specialists of Central Illinois, S.C., Decatur

62701

Central Illinois Hematology Oncology Center, Springfield

77030

University of Texas - MD Anderson Cancer Center, Houston

46885-5099

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER

NCT00003557 - Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer | Biotech Hunter | Biotech Hunter